Invex Therapeutics Stock Working Capital
| IXC Stock | 0.07 0 4.29% |
Invex Therapeutics fundamentals help investors to digest information that contributes to Invex Therapeutics' financial success or failures. It also enables traders to predict the movement of Invex Stock. The fundamental analysis module provides a way to measure Invex Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Invex Therapeutics stock.
Net Working Capital is likely to drop to about 5.4 M in 2024. Change In Working Capital is likely to gain to about (857.1 K) in 2024. Invex | Working Capital |
Invex Therapeutics Company Working Capital Analysis
Invex Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Invex Therapeutics Working Capital | 5.69 M |
Most of Invex Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Invex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Invex Net Invested Capital
Net Invested Capital |
|
According to the company's disclosures, Invex Therapeutics has a Working Capital of 5.69 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The working capital for all Australia stocks is notably lower than that of the firm.
Invex Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Invex Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Invex Therapeutics could also be used in its relative valuation, which is a method of valuing Invex Therapeutics by comparing valuation metrics of similar companies.Invex Therapeutics is currently under evaluation in working capital category among its peers.
Invex Fundamentals
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0922 | ||||
| Profit Margin | (1.35) % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | (989.76 K) | ||||
| Shares Outstanding | 75.15 M | ||||
| Shares Owned By Insiders | 67.72 % | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 4.15 X | ||||
| Revenue | 1.21 M | ||||
| Gross Profit | 459.08 K | ||||
| EBITDA | (720.44 K) | ||||
| Net Income | (1.64 M) | ||||
| Total Debt | 431.63 K | ||||
| Book Value Per Share | 0.08 X | ||||
| Cash Flow From Operations | (2.44 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 5.04 M | ||||
| Total Asset | 6.12 M | ||||
| Retained Earnings | (19.22 M) | ||||
| Working Capital | 5.69 M | ||||
| Annual Yield | 2.78 % | ||||
| Net Asset | 6.12 M |
About Invex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Invex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Invex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Invex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Invex Stock Analysis
When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.